

Infliximab

Selected References:

- Babuna Kobaner G, Polat Ekinci A. 2020. Infliximab for the treatment of recalcitrant generalized pustular psoriasis of pregnancy: Report of a challenging case. *Dermatologic Therapy*. 33(4): e13571
- Bendaoud, S, et al. 2024. Risk of anti-TNF therapy on pregnancy, breastfeeding, live vaccines and related information in patients with inflammatory bowel disease: Real-world data from a nationwide study. *Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver*, 56(12), 2038-2044.
- Bröms G, et al. 2020. Anti-TNF treatment during pregnancy and birth outcomes: A population-based study from Denmark, Finland, and Sweden. *Pharmacoepidemiol Drug Saf*. 29(3):316-327.
- Beaulieu DB, et al. 2018. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. *Clin Gastroenterol Hepatol*. 16:99-105. Carter JD, et al. 2009. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. *J Rheumatol*. 36(3):635-41. Chaparro M, Gisbet JP. 2014. How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease. *Expert Opin Drug Saf*. 13(12):1749-62.
- Dernoncourt A, et al. 2023. Fetal and neonatal adverse drug reactions associated with biologics taken during pregnancy by women with autoimmune diseases: insights from an analysis of the World Health Organization Pharmacovigilance Database (VigiBase®). *BioDrugs*. 37(1):73-87.
- Geldhof A, et al. 2020. Exposure to infliximab during pregnancy: Post-marketing experience. *Drug Saf*. 43(2):147-161.
- Goulden B, et al. 2022. A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero. *Rheumatology (Oxford)*. 6;61(10):3902-3906.
- Grgić, D., et al. 2020. Pregnancy-onset acute severe colitis after in vitro fertilization embryo transfer. *Case reports in gastroenterology*. 14(3):477-482.
- Heller MM, et al. 2011. Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab. *J Am Acad Dermatol*. 65(4):870.
- Kanis SL, et al. 2021. Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. *Gut*. 70(7):1266-1274.
- Kimberlin, D, et al. 2021. «Rotavirus Infections», Red Book: 2021–2024 Report of the Committee on Infectious Diseases, Committee on Infectious Diseases, American Academy of Pediatrics.
- Mahadevan U, et al. 2013. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. *Clin Gastroenterol Hepatol*. 11(3):286-92.
- Mahadevan U, et al. 2021. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. *Gastroenterology*. 160(4):1131-1139.
- Meserve J, et al. 2021. Paternal exposure to immunosuppressive and/or biologic agents and birth outcomes in patients with immune-mediated inflammatory diseases. *Gastroenterology*. 161(1):107-115.e3.
- Micu MC, et al. 2014. TNF- α inhibitors do not impair sperm quality in males with ankylosing spondylitis after short-term or long-term treatment. *Rheumatology (Oxford)*. 53(7):1250-5.
- Mouyis M, et al. 2019. Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence. *Semin Arthritis Rheum*. 48(5):911-920.
- Saougou I, et al. 2013. Fertility in male patients with seronegative spondyloarthropathies treated with infliximab. *Joint Bone Spine*. 80(1):34-37.
- Snoeckx Y, et al. 2008. Pregnancy outcomes in women taking infliximab: The infliximab safety database. *Arthr Rheum*. 58:S426.
- Weber-Schoendorfer C, et al. 2015. Pregnancy outcome after TNF- α inhibitor therapy during the first trimester: a prospective multicentre cohort study. *British Journal of Clinical Pharmacology*. 80(4):727-739.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2025.

Infliximab

Selected References:

- American College of Obstetrics and Gynecology. 2018. ACOG Practice Bulletin No. 189: nausea and vomiting of pregnancy. *Obstet Gynecol*, 131(1):e15-e30.
- Arsenault MY, et al. 2002. The management of nausea and vomiting of pregnancy. *J Obstet Gynaecol Can*, 24(10):817-831.
- Ashkenazi-Hoffnung L, et al. 2013. Evaluation of the efficacy and safety of bi-daily combination therapy with pyridoxine and doxylamine for nausea and vomiting of pregnancy. *Isr Med Assoc J*, 15(1):23-26.
- Atanackovic G. 2001. The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy. *J Clin Pharmacol*, 41(8):842-845.
- Banihani S. A. (2017). A Systematic Review Evaluating the Effect of Vitamin B6 on Semen Quality. *Urology journal*, 15(1), 1-5.
- Berard A, et al. 2019. New evidence for concern over the risk of birth defects from medications for nausea and vomiting of pregnancy. *J Clin Epidemiol*, 116: 39-48.
- Brent RL. 1995. Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen-litigen. *Reprod Toxicol*, 9(4):337-349.
- Dayan-Schwartz A, et al. 2024. The efficiency of cabergoline vs pyridoxine for lactation inhibition-a randomized controlled trial. *Am J Obstet Gynecol*. 2024 May;230(5):561.e1-561.e8.
- Einarson TR, et al. 1988. A method for meta-analysis of epidemiological studies. *Drug Intell Clin Pharm*, 22:813-824.
- Faraoni L, et al. 2020. Doxylamine use in pregnancy and neonatal abstinence syndrome: A case report. *Reprod Toxicol*, 97:6.
- Fisher A, et al. 2022. Patterns of antiemetic medication use during pregnancy: a multi-country retrospective cohort study. *Plos One*, 17(12):1-14.
- Guala, A, et al. 2022. Vitamin B6 Neonatal Toxicity. *Case reports in pediatrics*, 2022,
- Hansen C, et al. 2020. Use of antihistamine medications during early pregnancy and selected birth defects: The National Birth Defects Prevention Study, 1997-2011. *Birth Defects Res*, 112:1234-1252.
- He L, et al. 2024 The potential hazards of high doses of vitamin B6 in treating nausea and vomiting in

pregnancy: A systematic review. *Int J Gynaecol Obstet.* 10.1002/ijgo.16032

- Ito S, et al. 1993. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. *Am J Obstet Gynecol*, 168:1393-1399.
- Koren G, et al. 2015. Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial. *BMC Pregnancy Childbirth*, 15:59.
- Kutcher JS, et al. 2003. Bendectin and birth defects. II: Ecological analyses. *Birth Defects Res A Clin Mol Teratol*, 67:88-97.
- Madjunkova S, et al. 2014. The delayed-release combination of doxylamine and pyridoxine (Diclegis®/Diclectin®) for the treatment of nausea and vomiting of pregnancy. *Pediatr Drugs*, 16:199-211.
- Matthews A, et al. 2015. Interventions for nausea and vomiting in early pregnancy. *Cochrane Database Syst Rev*, (9):CD007575.
- McKeigue PM, et al. 1994. Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies. *Teratology*, 50:27-37.
- Nuangchamnog N, Niebyl J. 2014. Doxylamine succinate-pyridoxine hydrochloride (Diclegis) for the management of nausea and vomiting in pregnancy: an overview. *Int J Wom Health*, 6:401-9.
- Nulman I, et al. 2009. Long-term neurodevelopment of children exposed to maternal nausea and vomiting of pregnancy and Diclectin. *J Pediatr*, 155(1):45-50.
- Nulman I, Koren G. 2009. Pharmacokinetic comparison of a delayed-release combination of doxylamine succinate and pyridoxine hydrochloride (Diclectin) and oral solutions of these drugs in healthy women of childbearing age. *Can J Clin Pharmacol.* 16(3):29.
- Persaud N, et al. 2018. Doxylamine-pyridoxine for nausea and vomiting of pregnancy randomized placebo controlled trial: Prespecified analyses and reanalysis. *Plos One*, 13(1):e0189978.
- Schragar, N. L., et al. & for the National Birth Defects Prevention Study. 2023. The association of nausea and vomiting of pregnancy, its treatments, and select birth defects: Findings from the National Birth Defect Prevention Study. *Birth defects research*, **115**(3), 275–289.
- Shrateh ON, et al. 2024. Comparing pyridoxine with dopaminergic agonists (cabergoline and bromocriptine): Unveiling the strategy for lactation inhibition – A systematic review of clinical trials. *J Gynecol Obstet Hum Reprod.* 2024 Jun;53(6):102783.
- Tyl RW, et al. 1988. Developmental toxicity evaluation of Bendectin in CD rats. *Teratology*, 37:539-552.
- Wu, X., et al. 2023. Acupuncture and Doxylamine-Pyridoxine for Nausea and Vomiting in Pregnancy : A Randomized, Controlled, 2 × 2 Factorial Trial. *Annals of internal medicine*, 176(7), 922–933.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2025.

Infliximab

Selected References:

- Ali Sakr Esa W, et al. 2009. Epidural analgesia in labor for a woman with an intrathecal baclofen pump. *Int J Obstet Anesth*. 2009 Jan;18(1):64-6.
- Andrade C. 2020. Individualized, High-Dose Baclofen for Reduction in Alcohol Intake in Persons With High Levels of Consumption, *J Clin Psychiatry*. Aug 4;81(4):20f13606.
- Baclofen Product Label. 2023: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04dac0f6-cc6c-4959-9bca-a6e4a99690f3>. Accessed 11/2024.
- Balakirouchenane D, et al. 2021. Pharmacokinetics of Baclofen in a Full-Term Newborn after Intrauterine Exposure: A Case Report. *Neonatology*; 118(5):624-627.
- Barker KDD, et al. 2025. Three consecutive pregnancies in a woman with spastic cerebral palsy being treated with intrathecal baclofen therapy. *Int J Gynaecol Obstet*;168(3):893-895.
- Bernard N, et al. 2012. Pregnancy outcomes after in utero exposure to baclofen. *Reprod Toxicol*; 34(2):157.
- Briggs, GG and Freeman RK. 2016. *Drugs in Pregnancy and Lactation*, Tenth Edition; Wolters Kluwer. 122-3.
- Dalton CM, et al. 2008. The safety of baclofen in pregnancy: intrathecal therapy in multiple sclerosis. *Mult Scler*; 14(4):571-2.
- Delhaas EM, Verhagen J. 1992. Pregnancy in a quadriplegic patient treated with continuous intrathecal baclofen infusion to manage her severe spasticity. *Case report. Paraplegia*; 30: 527-8.
- Engrand N, et al. 2001. Intrathecal baclofen for severe tetanus in a pregnant woman. *Eur J Anaesthesiol*; 18:261-3.
- Eriksson G, Swahn CG. 1981. Concentrations of baclofen in serum and breast milk from a lactating woman. *Scand J Clin Lab Invest*; 41(2):185-7.
- Freeman, EH and Delaney, RM. 2016. Neonatal Baclofen Withdrawal: A Case Report of an Infant Presenting with Severe Feeding Difficulties. *J Pediatr Nurs*. May-Jun: 31(3):346-9.
- Goldkamp J, et al. 2011. Stiff person syndrome and pregnancy. *Obstet Gynecol*; 118(2 Pt 2):454-457.
- Hale TW and Rowe HE. 2015. *Medications and Mother's Milk 2017*. Springer Publishing Co. 93-4.
- Hara T, et al. 2018. Pregnancy and breastfeeding during intrathecal baclofen therapy - A case study and review. *NMC Case Rep J*. Jun 25;5(3):65-8.
- Hyser, CL and Drake, ME. 1984. Status Epilepticus after Baclofen Withdrawal. *J Natl Med Assoc*; 76(5):533, 537-8.
- Lin HH, et al. 2014. Baclofen distribution into breast milk-a potential for toxicity? *J Med Toxicol*; 10:86.
- Lin HH, et al. 2014. Prevention of neonatal abstinence syndrome in the setting of intrauterine baclofen exposure. *J Med Toxicol*; 10:85-6.
- Logge WB, et al. 2020. Baclofen modulates cardiovascular responses to appetitive cues in treatment-seeking

alcohol use disorder individuals. Hum Psychopharmacol. Mar;35(2):e2722.

- Mahdavinassab SM, et al. 2019. Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial. Eur Child Adolesc Psychiatry. Dec;28(12):1619-1628.
- Mendez-Lucena C, et al. 2014. Intrathecal baclofen for dystonia treatment during pregnancy: A case report. Neurologia; 31(2): 131-132.
- Moran LR, et al. 2004. Intrauterine Baclofen Exposure: A Multidisciplinary Approach. Pediatrics; 114(2): e267-8.
- Morton CM, et al. 2009. Intrathecal baclofen administration during pregnancy: a case series and focused clinical review. PM R. Nov;1(11):1025-9.
- Mousigian MA, et al. 2022. Neonatal baclofen withdrawal following intrauterine exposure. J Pediatr Rehabil Med; 15(2):389-394.
- Muñoz FC et al. 2020. Pregnancy outcome in a woman exposed to continuous intrathecal baclofen infusion. Ann Pharmacother. Jul-Aug 2000;34(7-8):956
- Ratnayaka BD, et al. 2001. Drug points: Neonatal convulsions after withdrawal of baclofen. BMJ. Jul 14;323(7304):85.
- Roberts AG, et al. 2003. Intrathecal baclofen pump implantation during pregnancy. Neurology; 61:1156-7.
- Weatherby SJ, et al. 2004. Pregnancy in stiff-limb syndrome. Mov Disord; 19(7):852-4.
- Yang K, et al. 2024. Intrathecal baclofen pump in pregnancy: case report, literature review, and management considerations. Reg Anesth Pain Med; 49(12):919-922.

[¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .](#)

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2025.

Infliximab

Selected References:

- American Academy of Pediatrics. 2009. Varicella-zoster infections. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2009. Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL:

American Academy of Pediatrics;714-727

- Arthur I. Eidelman, et al. 2012. Breastfeeding and the Use of Human Milk. *Pediatrics* March 2012; 129 (3): e827–e841.
- Bohlke K, et al. 2003. Postpartum varicella vaccination: is the vaccine virus excreted in breast milk? *Obstet Gynecol* 102(5 Pt 1):970-977.
- Centers for Disease Control and Prevention. 1996. Prevention of varicella. *MMWR*; 45(RR-11);1-36.
- Centers for Disease Control and Prevention. 2013. Updated Recommendations for Use of VariZIG — United States, 2013. *MMWR*. 62(28)574-576.
- Centers for Disease Control and Prevention. 2016. Guidelines for vaccinating pregnant women (2012, updated 2016). <http://www.cdc.gov/vaccines/pubs/preg-guide.htm>
- Chan DYL, et al. 2017. Human varicella zoster virus is not present in the semen of a man affected by chickenpox during the in vitro fertilisation of his wife. *Andrologia* 49(10):e12822.
- Cohen A, et al. Congenital varicella syndrome: the evidence for secondary prevention with varicella-zoster immune globulin. *CMAJ*:183(2):204-208.
- Committee on Infectious Diseases, American Academy of Pediatrics. 1995. Recommendations for the use of live attenuated varicella vaccine. *Pediatrics*; 95:791-796.
- Enders, G et al. 1994. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases." *Lancet (London, England)* vol. 343,8912: 1548-51.
- Fabiano, Valentina et al. 2013. Herpes zoster in an immunocompetent boy following intrauterine exposure to varicella-zoster virus." *Cutis* vol. 91,3: 127-8, 140.
- Frederick IB, et al. 1986. Excretion of varicella-herpeszoster in breast milk. *Am J Obstet Gynecol*; 154:1116-1117.
- Gruslin A, et al; SOGC. 2008. Immunization in pregnancy: No. 220, December 2008. *Int J Gynaecol Obstet*; 105(2):187-191.
- Harger, James H et al. 2002. Frequency of congenital varicella syndrome in a prospective cohort of 347 pregnant women." *Obstetrics and gynecology* vol. 100,2: 260-5.
- Hayward K, et al. 2018. Management of herpes zoster (shingles) during pregnancy. *J Obstet Gynaecol* 38(7):887-894.
- Konopka, A., Szczepaniak, Z., Wdowiak, N., Lissak, K., Komarów, M., Choinka, M., ... Kalisiak, J. (2024). A Comprehensive Review of TORCH Syndrome: Characterization and Prevention Strategies. *Quality in Sport*, 21, 53987.
- Lamont, Ronald F et al. 2011. Varicella-zoster virus (chickenpox) infection in pregnancy." *BJOG : an international journal of obstetrics and gynaecology* vol. 118,10: 1155-62.
- Marin M, et al. 2013. Closure of Varicella-Zoster Virus-Containing Vaccines Pregnancy Registry – United States. *MMWR*. 63(33);732-733.
- Mohsin, M. S., Gaballa, N. F., & Elsayed, W. (2024). Varicella Orchitis: A Case Report and Literature Review. *Cureus*, 16(8), e66978.
- National Center for Immunization and Respiratory Diseases. 2011. General recommendations on immunization — recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 60(2):1-64. Erratum in: *MMWR Recomm Rep*. 2011:60:993.
- Petignat, P et al. 2001. Fetal varicella-herpes zoster syndrome in early pregnancy: ultrasonographic and morphological correlation. *Prenatal diagnosis* vol. 21,2 (2001): 121-4.
- Tan MP, Koren G. 2006. Chickenpox in pregnancy: revisited. *Reprod Toxicol*; 21(4):410-20.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2025.

Infliximab

Selected References:

- Aagaard J, et al. 1991. Prostatic tissue levels of ofloxacin. *Urology*, 38:380-382.
- Cahill JB Jr, et al. 2005. Levofloxacin secretion in breast milk: a case report. *Pharmacotherapy*, 25:116-118.
- Caplin Sterile Limited. 2024. Ofloxacin product label. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo>. Accessed June 20 2024.
- Danisovicova A, et al. 1994. Magnetic resonance imaging in children receiving quinolones: no evidence of quinolone-induced arthropathy. A multicenter survey. *Chemotherapy*, 40:209-214.
- Drobac PC, et al. 2005. Treatment of multidrug-resistant tuberculosis during pregnancy: long-term follow-up of 6 children with intrauterine exposure to second-line agents. *Clin Infect Dis*, 40:1689-1692.
- Erhart B, et al. 1998. Ofloxacin: the next generation of antibiotic in sperm and embryo cultures for assisted reproductive technologies. *Fertil Steril*, 69(2):246-251.
- Falagas ME, et al. 2007. Arrhythmias associated with fluoroquinolone therapy. *Int J Antimicrob Agents*, 29(4):374-379.
- Giamarellou H, et al. 1989. Pharmacokinetics of three newer quinolones in pregnant and lactating women. *Am J Med*, 87(5A):49S-51S.
- Loebstein R, et al. 1998. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. *Antimicrob Agents Chemother*, 42:1336-1339.
- Muanda Ft, et al. 2017. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. *Br J Clin Pharmacol*, 83:2557-2571.
- Naber KG, et al. 1993. Penetration of ofloxacin into prostatic fluid, ejaculate and seminal fluid. *Infection*, 21(2):98-100.
- Nivagen Pharmaceuticals Inc. 2023. Ofloxacin product label. Available at: <https://dailymed.nlm.nih.gov/dailymed/drugInfo>. Accessed June 20 2024.
- Padberg S, et al. 2014. Observational cohort study of pregnancy outcomes after first-trimester exposure to fluoroquinolones. *Antimicrob Agents Chemother*, 58(8):4392-4398.
- Peled Y, et al. 1991. Ofloxacin during the second trimester of pregnancy. *DICP*, 25(11):1181-1182.
- Schaefer C, et al. 1996. Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS). *Eur J Obstet Gynecol Reprod Biol*, 69(2):83-89.
- Schramm P. 1986. Ofloxacin: concentration in human ejaculate and influence on sperm motility. *Infection*, 14 Suppl 4:S274-S275.
- Shao S, et al. 2023. Association between antibiotic exposure and the risk of infertility in women of childbearing age: a case-control study. *Ecotoxicol Environ Saf*, 249: 114414.

- Shin YJ, et al. 2018. Pregnancy outcomes in women reporting exposure to ofloxacin in early pregnancy. J Obstet Gynaecol, 38(6):807-812.
- Wilton LV, et al. 1998. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. British J Obstet Gynecol, 105:882-889.
- Yamaguchi H, et al. 2007. Post-marketing surveillance of the safety of levofloxacin in Japan. Chemotherapy, 53(2):85-103.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2025.